Clinical evaluation of a novel chemiluminescent immunoassay for the detection of anti-citrullinated peptide antibodies

Clinica Chimica Acta

Volumn 437, Issue , 2014, Pages 161-167

  Webb, Tyler ^a   Lakos, Gabriella ^a   Swart, Andreas ^b   Gürtler, Irmgard ^b   Favalli, Ennio Giulio ^c   Schioppo, Tommaso ^c   Mahler, Michael ^b  

^a INOVA DIAGNOSTICS INC   (United States)

^b Center for Rheumatic Diseases   (Germany)

^c ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

Author keywords

Autoantibodies; CCP; Citrullinated cyclic peptide; RA; Rheumatoid arthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR; AUTOANTIBODY; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ADULT; ANTIBODY DETECTION; AREA UNDER THE CURVE; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EVALUATION STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; MEASUREMENT PRECISION; PREDICTIVE VALUE; PRIORITY JOURNAL; RAPID TEST; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; AGED; ARTHRITIS, RHEUMATOID; BLOOD; COHORT ANALYSIS; LUMINESCENCE; MIDDLE AGED; PROCEDURES; STANDARDS;

AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; HUMANS; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC;

EID: 84907342143     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.07.032     Document Type: Article

References (47)

1. van Venrooij W.J., van Beers J.J., Pruijn G.J. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol 2011, 7:391-398.
2. Wiik A.S., van Venrooij W.J., Pruijn G.J. All you wanted to know about anti-CCP but were afraid to ask. Autoimmun Rev 2010, 10:90-93.
3. Schellekens G.A., de Jong B.A., van den Hoogen F.H., van de Putte L.B., van Venrooij W.J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998, 101:273-281.
4. Aletaha D., Neogi T., Silman A.J., et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62:2569-2581.
5. Aletaha D., Neogi T., Silman A.J., et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010, 69:1580-1588.
6. Kessenbrock K., Raijmakers R., Fritzler M.J., Mahler M. Synthetic peptides: the future of patient management in systemic rheumatic diseases?. Curr Med Chem 2007, 14:2831-2838.
7. Levesque M.C., Zhou Z., Moreland L.W. Anti-cyclic citrullinated peptide testing for the diagnosis of rheumatoid arthritis and the quest for improved sensitivity and predictive value. Arthritis Rheum 2009, 60:2211-2215.
8. Vander C.B., Nogueira L., Van P.J., et al. Do all anti-citrullinated protein/peptide antibody tests measure the same? Evaluation of discrepancy between anti-citrullinated protein/peptide antibody tests in patients with and without rheumatoid arthritis. Ann Rheum Dis 2008, 67:542-546.
9. Bizzaro N., Tonutti E., Tozzoli R., Villalta D. Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem 2007, 53:1527-1533.
10. Santiago M., Baron M., Miyachi K., et al. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol 2008, 27:77-83.
11. Correia M.L., Carvalho S., Fortuna J., Pereira M.H. Comparison of three anti-CCP antibody tests and rheumatoid factor in RA and control patients. Clin Rev Allergy Immunol 2008, 34:21-25.
12. van der Linden M.P., van der Woude D., Ioan-Facsinay A., et al. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 2009, 60:2232-2241.
13. Jaskowski T.D., Hill H.R., Russo K.L., Lakos G., Szekanecz Z., Teodorescu M. Relationship between rheumatoid factor isotypes and IgG anti-cyclic citrullinated peptide antibodies. J Rheumatol 2010, 37:1582-1588.
14. Coenen D., Verschueren P., Westhovens R., Bossuyt X. Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 2007, 53:498-504.
15. Machold K.P., Stamm T.A., Nell V.P., et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 2007, 46:342-349.
16. van Venrooij W.J., Zendman A.J., Pruijn G.J. Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev 2006, 6:37-41.
17. Pruijn G.J., Wiik A., van Venrooij W.J. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther 2010, 12:203.
18. Bossuyt X., Coenen D., Fieuws S., Verschueren P., Westhovens R., Blanckaert N. Likelihood ratios as a function of antibody concentration for anti-cyclic citrullinated peptide antibodies and rheumatoid factor. Ann Rheum Dis 2009, 68:287-289.
19. Pratesi F., Tommasi C., Anzilotti C., et al. Antibodies to a new viral citrullinated peptide, VCP2: fine specificity and correlation with anti-cyclic citrullinated peptide (CCP) and anti-VCP1 antibodies. Clin Exp Immunol 2011, 164:337-345.
20. Bartoloni E., Alunno A., Bistoni O., et al. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. Autoimmun Rev 2014, [in press].
21. Dejaco C., Klotz W., Larcher H., Duftner C., Schirmer M., Herold M. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006, 8:R119.
22. Soos L., Szekanecz Z., Szabo Z., et al. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol 2007, 34:1658-1663.
23. Damjanovska L., Thabet M.M., Levarth E.W., et al. Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis. Ann Rheum Dis 2010, 69:730-732.
24. Nell V.P., Machold K.P., Stamm T.A., et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 2005, 64:1731-1736.
25. Chandra P.E., Sokolove J., Hipp B.G., et al. Novel multiplex technology for diagnostic characterization of rheumatoid arthritis. Arthritis Res Ther 2011, 13:R102.
26. Shoda H., Fujio K., Shibuya M., et al. Detection of autoantibodies to citrullinated BiP in rheumatoid arthritis patients and pro-inflammatory role of citrullinated BiP in collagen-induced arthritis. Arthritis Res Ther 2011, 13:R191.
27. Infantino M., Manfredi M., Meacci F., et al. Anti-citrullinated peptide antibodies and rheumatoid factor isotypes in the diagnosis of rheumatoid arthritis: an assessment of combined tests. Clin Chim Acta 2014, [Epub 2014 Jun 2].
28. Debaugnies F., Servais G., Badot V., Noubouossie D., Willems D., Corazza F. Anti-cyclic citrullinated peptide antibodies: a comparison of different assays for the diagnosis of rheumatoid arthritis. Scand J Rheumatol 2013, 42:108-114.
29. Swart A., Burlingame R.W., Gurtler I., Mahler M. Third generation anti-citrullinated peptide antibody assay is a sensitive marker in rheumatoid factor negative rheumatoid arthritis. Clin Chim Acta 2012, 414:266-272.
30. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
31. dos Anjos L.M., Pereira I.A., 'Orsi E., Seaman A.P., Burlingame R.W., Morato E.F. A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis. Clin Rheumatol 2009, 28:153-158.
32. Silveira I.G., Burlingame R.W., von Muhlen C.A., Bender A.L., Staub H.L. Anti-CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF. Clin Rheumatol 2007, 26:1883-1889.
33. Rottmann M. Anti-CCP: challenges in quantifying auto-antibodies and creating international reference materials. Scand J Clin Lab Invest Suppl 2010, 242:44-45.
34. Bizzaro N., Pregnolato F., van Boekel M.A., et al. Preliminary evaluation of the first international reference preparation for anticitrullinated peptide antibodies. Ann Rheum Dis 2012, 71:1388-1392.
35. Willemze A., Bohringer S., Knevel R., et al. The ACPA recognition profile and subgrouping of ACPA-positive RA patients. Ann Rheum Dis 2012, 71:268-274.
36. Trouw L.A., Mahler M. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun Rev 2012, 12:318-322.
37. Kokkonen H., Mullazehi M., Berglin E., et al. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther 2011, 13:R13.
38. Rakieh C., Nam J.L., Hunt L., et al. Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study. Ann Rheum Dis 2014, [Epub 2014 Apr 12].
39. Shi J., van de Stadt L.A., Levarht E.W., et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis 2014, 73:780-783.
40. Mahler M., Meroni P.L., Bossuyt X., Fritzler M.J. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res 2014, 2014:315179.
41. Cader M.Z., Filer A., Hazlehurst J., de P.P., Buckley C.D., Raza K. Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis: comparison with 1987 ACR criteria in a very early synovitis cohort. Ann Rheum Dis 2011, 70:949-955.
42. Fautrel B., Combe B., Rincheval N., Dougados M. Level of agreement of the 1987 ACR and 2010 ACR/EULAR rheumatoid arthritis classification criteria: an analysis based on ESPOIR cohort data. Ann Rheum Dis 2012, 71:386-389.
43. Tebo A.E., Jaskowski T., Davis K.W., et al. Profiling anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2012, 10:29.
44. Omar A., Abo-Elyoun I., Hussein H., et al. Anti-cyclic citrullinated peptide (anti-CCP) antibody in juvenile idiopathic arthritis (JIA): correlations with disease activity and severity of joint damage (a multicenter trial). Joint Bone Spine 2013, 80:38-43.
45. Avcin T., Cimaz R., Falcini F., et al. Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2002, 61:608-611.
46. Somers K., Geusens P., Elewaut D., et al. Novel autoantibody markers for early and seronegative rheumatoid arthritis. J Autoimmun 2011, 36:33-46.
47. Shi J., Knevel R., Suwannalai P., et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A 2011, 108:17372-17377.